Constellation is changing the way the world sees skin cancer.

The first imaging system to provide full-body skin mapping and ongoing monitoring. Lightweight, affordable, and convenient.

Mark Murcko

Posted on 29 May 2013 Comments Off



Mark Murcko, PhD


Mark Murcko has more than 25 years of biomedical experience; is a current or former member of more than 10 journal editorial boards, 9 Scientific Advisory Boards, and 2 Boards of Directors; and has academic appointments at MIT and Northeastern University.

Until November 2011 he was Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals. In this role, he was responsible for the identification, validation, and incorporation of disruptive technologies across global R&D. Mark is a co-inventor of Incivek™ (telaprevir), the world’s most widely prescribed HCV protease inhibitor, as well as Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex’s two marketed drugs for HIV. He is also a co-inventor of 8 other clinical candidates in the areas of cancer, inflammation/immunology, and infectious disease and was responsible for starting many of Vertex’s programs in these and other disease areas. Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, Trusopt™ (dorzolamide), became the first marketed drug in pharmaceutical history to result from a structure-based drug design program.

Mark is highly regarded as an innovator. He has served on the editorial boards of many scientific publications, including the Journal of Medicinal Chemistry, Drug Discovery Today, and the Journal of Disruptive Science and Technology, was the co-organizer of the 2008 ACS National Medicinal Chemistry Symposium, and will serve as the Chair of the 2013 Gordon Research Conference in Medicinal Chemistry. He is a co-inventor on more than 40 issued patents and has co-authored more than 85 scientific articles, and has delivered more than 130 invited lectures. He received his Ph.D. in physical organic chemistry from Yale University.

We're moving fast. Keep up through email alerts.

We respect your inbox.